COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development
The COVID‐19 pandemic has unfolded to be the most challenging global health crisis in a century. In 11 months since its first emergence, according to WHO, the causative infectious agent SARS‐CoV‐2 has infected more than 100 million people and claimed more than 2.15 million lives worldwide. Moreover,...
Gespeichert in:
| Veröffentlicht in: | The FASEB journal 2021-03, Vol.35 (3), p.e21409-n/a |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 3 |
| container_start_page | e21409 |
| container_title | The FASEB journal |
| container_volume | 35 |
| creator | Singh, Ramandeep Kang, Alisha Luo, Xiangqian Jeyanathan, Mangalakumari Gillgrass, Amy Afkhami, Sam Xing, Zhou |
| description | The COVID‐19 pandemic has unfolded to be the most challenging global health crisis in a century. In 11 months since its first emergence, according to WHO, the causative infectious agent SARS‐CoV‐2 has infected more than 100 million people and claimed more than 2.15 million lives worldwide. Moreover, the world has raced to understand the virus and natural immunity and to develop vaccines. Thus, within a short 11 months a number of highly promising COVID‐19 vaccines were developed at an unprecedented speed and are now being deployed via emergency use authorization for immunization. Although a considerable number of review contributions are being published, all of them attempt to capture only a specific aspect of COVID‐19 or its therapeutic approaches based on ever‐expanding information. Here, we provide a comprehensive overview to conceptually thread together the latest information on global epidemiology and mitigation strategies, clinical features, viral pathogenesis and immune responses, and the current state of vaccine development. |
| doi_str_mv | 10.1096/fj.202002662R |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7898934</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2489247029</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5709-2a3c956344616e107d975ea95b5e68165e3600e68753eea03bb93e015e79a21a3</originalsourceid><addsrcrecordid>eNp9kb9uFDEQhy0EIkegpEVbUrBhbK-9awokOJIQKVIk_rWWzzt7-PDah317Ubo8As_Ik8ThkhAaqhnNfPrG8o-Q5xQOKCj5elgdMGAATEr26QGZUcGhlp2Eh2QGnWK1lLzbI09yXgEABSofkz3ORdtSKmakn599O_nw-_IXVW-q-ZQShk31I8Rzj_0SKxcq611w1vhqQLOZEuZXlRvHKUQfl3_mZbSOIV8vTOirrbHWBax63KKP67EIn5JHg_EZn93UffL16PDL_GN9enZ8Mn93WlvRgqqZ4VYJyZtGUokU2l61Ao0SC4Gyo1IglwClbQVHNMAXC8URqMBWGUYN3ydvd971tBixt-V0Ml6vkxtNutDROP3vJrjvehm3uu1Up3hTBC9vBCn-nDBv9OiyRe9NwDhlzZryo00LTBW03qE2xZwTDndnKOjrZPSw0n-TKfyL-2-7o2-jKECzA86dx4v_2_TR5_eM0QYUvwJHI5pz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2489247029</pqid></control><display><type>article</type><title>COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Singh, Ramandeep ; Kang, Alisha ; Luo, Xiangqian ; Jeyanathan, Mangalakumari ; Gillgrass, Amy ; Afkhami, Sam ; Xing, Zhou</creator><creatorcontrib>Singh, Ramandeep ; Kang, Alisha ; Luo, Xiangqian ; Jeyanathan, Mangalakumari ; Gillgrass, Amy ; Afkhami, Sam ; Xing, Zhou</creatorcontrib><description>The COVID‐19 pandemic has unfolded to be the most challenging global health crisis in a century. In 11 months since its first emergence, according to WHO, the causative infectious agent SARS‐CoV‐2 has infected more than 100 million people and claimed more than 2.15 million lives worldwide. Moreover, the world has raced to understand the virus and natural immunity and to develop vaccines. Thus, within a short 11 months a number of highly promising COVID‐19 vaccines were developed at an unprecedented speed and are now being deployed via emergency use authorization for immunization. Although a considerable number of review contributions are being published, all of them attempt to capture only a specific aspect of COVID‐19 or its therapeutic approaches based on ever‐expanding information. Here, we provide a comprehensive overview to conceptually thread together the latest information on global epidemiology and mitigation strategies, clinical features, viral pathogenesis and immune responses, and the current state of vaccine development.</description><identifier>ISSN: 0892-6638</identifier><identifier>EISSN: 1530-6860</identifier><identifier>DOI: 10.1096/fj.202002662R</identifier><identifier>PMID: 33577115</identifier><language>eng</language><publisher>United States: John Wiley and Sons Inc</publisher><subject>Animals ; COVID-19 - immunology ; COVID-19 - prevention & control ; COVID-19 Vaccines - immunology ; COVID‐19 ; Humans ; immunity ; Immunity - immunology ; Immunization - methods ; Pandemics - prevention & control ; Review ; Reviews ; SARS-CoV-2 - immunology ; SARS‐CoV‐2 ; therapy ; vaccines</subject><ispartof>The FASEB journal, 2021-03, Vol.35 (3), p.e21409-n/a</ispartof><rights>2021 The Authors. published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.</rights><rights>2021 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5709-2a3c956344616e107d975ea95b5e68165e3600e68753eea03bb93e015e79a21a3</citedby><cites>FETCH-LOGICAL-c5709-2a3c956344616e107d975ea95b5e68165e3600e68753eea03bb93e015e79a21a3</cites><orcidid>0000-0001-7856-0663</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1096%2Ffj.202002662R$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1096%2Ffj.202002662R$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33577115$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singh, Ramandeep</creatorcontrib><creatorcontrib>Kang, Alisha</creatorcontrib><creatorcontrib>Luo, Xiangqian</creatorcontrib><creatorcontrib>Jeyanathan, Mangalakumari</creatorcontrib><creatorcontrib>Gillgrass, Amy</creatorcontrib><creatorcontrib>Afkhami, Sam</creatorcontrib><creatorcontrib>Xing, Zhou</creatorcontrib><title>COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development</title><title>The FASEB journal</title><addtitle>FASEB J</addtitle><description>The COVID‐19 pandemic has unfolded to be the most challenging global health crisis in a century. In 11 months since its first emergence, according to WHO, the causative infectious agent SARS‐CoV‐2 has infected more than 100 million people and claimed more than 2.15 million lives worldwide. Moreover, the world has raced to understand the virus and natural immunity and to develop vaccines. Thus, within a short 11 months a number of highly promising COVID‐19 vaccines were developed at an unprecedented speed and are now being deployed via emergency use authorization for immunization. Although a considerable number of review contributions are being published, all of them attempt to capture only a specific aspect of COVID‐19 or its therapeutic approaches based on ever‐expanding information. Here, we provide a comprehensive overview to conceptually thread together the latest information on global epidemiology and mitigation strategies, clinical features, viral pathogenesis and immune responses, and the current state of vaccine development.</description><subject>Animals</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines - immunology</subject><subject>COVID‐19</subject><subject>Humans</subject><subject>immunity</subject><subject>Immunity - immunology</subject><subject>Immunization - methods</subject><subject>Pandemics - prevention & control</subject><subject>Review</subject><subject>Reviews</subject><subject>SARS-CoV-2 - immunology</subject><subject>SARS‐CoV‐2</subject><subject>therapy</subject><subject>vaccines</subject><issn>0892-6638</issn><issn>1530-6860</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp9kb9uFDEQhy0EIkegpEVbUrBhbK-9awokOJIQKVIk_rWWzzt7-PDah317Ubo8As_Ik8ThkhAaqhnNfPrG8o-Q5xQOKCj5elgdMGAATEr26QGZUcGhlp2Eh2QGnWK1lLzbI09yXgEABSofkz3ORdtSKmakn599O_nw-_IXVW-q-ZQShk31I8Rzj_0SKxcq611w1vhqQLOZEuZXlRvHKUQfl3_mZbSOIV8vTOirrbHWBax63KKP67EIn5JHg_EZn93UffL16PDL_GN9enZ8Mn93WlvRgqqZ4VYJyZtGUokU2l61Ao0SC4Gyo1IglwClbQVHNMAXC8URqMBWGUYN3ydvd971tBixt-V0Ml6vkxtNutDROP3vJrjvehm3uu1Up3hTBC9vBCn-nDBv9OiyRe9NwDhlzZryo00LTBW03qE2xZwTDndnKOjrZPSw0n-TKfyL-2-7o2-jKECzA86dx4v_2_TR5_eM0QYUvwJHI5pz</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Singh, Ramandeep</creator><creator>Kang, Alisha</creator><creator>Luo, Xiangqian</creator><creator>Jeyanathan, Mangalakumari</creator><creator>Gillgrass, Amy</creator><creator>Afkhami, Sam</creator><creator>Xing, Zhou</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7856-0663</orcidid></search><sort><creationdate>202103</creationdate><title>COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development</title><author>Singh, Ramandeep ; Kang, Alisha ; Luo, Xiangqian ; Jeyanathan, Mangalakumari ; Gillgrass, Amy ; Afkhami, Sam ; Xing, Zhou</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5709-2a3c956344616e107d975ea95b5e68165e3600e68753eea03bb93e015e79a21a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines - immunology</topic><topic>COVID‐19</topic><topic>Humans</topic><topic>immunity</topic><topic>Immunity - immunology</topic><topic>Immunization - methods</topic><topic>Pandemics - prevention & control</topic><topic>Review</topic><topic>Reviews</topic><topic>SARS-CoV-2 - immunology</topic><topic>SARS‐CoV‐2</topic><topic>therapy</topic><topic>vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singh, Ramandeep</creatorcontrib><creatorcontrib>Kang, Alisha</creatorcontrib><creatorcontrib>Luo, Xiangqian</creatorcontrib><creatorcontrib>Jeyanathan, Mangalakumari</creatorcontrib><creatorcontrib>Gillgrass, Amy</creatorcontrib><creatorcontrib>Afkhami, Sam</creatorcontrib><creatorcontrib>Xing, Zhou</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The FASEB journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singh, Ramandeep</au><au>Kang, Alisha</au><au>Luo, Xiangqian</au><au>Jeyanathan, Mangalakumari</au><au>Gillgrass, Amy</au><au>Afkhami, Sam</au><au>Xing, Zhou</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development</atitle><jtitle>The FASEB journal</jtitle><addtitle>FASEB J</addtitle><date>2021-03</date><risdate>2021</risdate><volume>35</volume><issue>3</issue><spage>e21409</spage><epage>n/a</epage><pages>e21409-n/a</pages><issn>0892-6638</issn><eissn>1530-6860</eissn><abstract>The COVID‐19 pandemic has unfolded to be the most challenging global health crisis in a century. In 11 months since its first emergence, according to WHO, the causative infectious agent SARS‐CoV‐2 has infected more than 100 million people and claimed more than 2.15 million lives worldwide. Moreover, the world has raced to understand the virus and natural immunity and to develop vaccines. Thus, within a short 11 months a number of highly promising COVID‐19 vaccines were developed at an unprecedented speed and are now being deployed via emergency use authorization for immunization. Although a considerable number of review contributions are being published, all of them attempt to capture only a specific aspect of COVID‐19 or its therapeutic approaches based on ever‐expanding information. Here, we provide a comprehensive overview to conceptually thread together the latest information on global epidemiology and mitigation strategies, clinical features, viral pathogenesis and immune responses, and the current state of vaccine development.</abstract><cop>United States</cop><pub>John Wiley and Sons Inc</pub><pmid>33577115</pmid><doi>10.1096/fj.202002662R</doi><tpages>23</tpages><orcidid>https://orcid.org/0000-0001-7856-0663</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0892-6638 |
| ispartof | The FASEB journal, 2021-03, Vol.35 (3), p.e21409-n/a |
| issn | 0892-6638 1530-6860 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7898934 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Animals COVID-19 - immunology COVID-19 - prevention & control COVID-19 Vaccines - immunology COVID‐19 Humans immunity Immunity - immunology Immunization - methods Pandemics - prevention & control Review Reviews SARS-CoV-2 - immunology SARS‐CoV‐2 therapy vaccines |
| title | COVID‐19: Current knowledge in clinical features, immunological responses, and vaccine development |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T05%3A50%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID%E2%80%9019:%20Current%20knowledge%20in%20clinical%20features,%20immunological%20responses,%20and%20vaccine%20development&rft.jtitle=The%20FASEB%20journal&rft.au=Singh,%20Ramandeep&rft.date=2021-03&rft.volume=35&rft.issue=3&rft.spage=e21409&rft.epage=n/a&rft.pages=e21409-n/a&rft.issn=0892-6638&rft.eissn=1530-6860&rft_id=info:doi/10.1096/fj.202002662R&rft_dat=%3Cproquest_pubme%3E2489247029%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2489247029&rft_id=info:pmid/33577115&rfr_iscdi=true |